Discovery and Translational Sciences|Pneumonia & Pandemic Preparedness | Pandemic PACT Tracker

Key facts

Disease
COVID-19, Severe Acute Respiratory Syndrome (SARS)…
Start & end year
2021
2024
Known Financial Commitments (USD)
$1,037,250
Funder
Gates Foundation
Research Location
United States of America
Lead Research Institution
California Institute of Technology
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

to develop Pan-sarbecovirus vaccine strategies

9 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated mice.

Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist.

Broad anti-sarbecovirus responses elicited by a single administration of mosaic-8 RBD-nanoparticle vaccine prepared using atomic layer deposition.

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated mice

Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles.

Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles

Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals.

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.